Introduction
HIV-1 Vpr is a 96-a.a. 14-kDa protein associated with the HIV virus particle (Cohen et al., 1990; Hrimech et al., 1999) . The role of Vpr in the transportation of the pre-integration complex into the nuclei of infected cells is well established. However, Vpr also inhibits cell proliferation through the induction of cell-cycle arrest and apoptosis in rapidly dividing cell lines including some tumor cell lines (Levy et al., 1993; He et al., 1995; Ayyavoo et al., 1997; Mahalingam et al., 1997; Goh et al., 1998; Subbramanian et al., 1998; Stewart et al., 2000) . It has been suggested that HIV-1 Vpr may have anti-tumor eects (Levy et al., 1993; Mahalingam et al., 1997; Stewart et al., 1999) . However, how Vpr induces apoptosis in tumor cell lines is not clearly understood. In order to further examine this aspect of Vpr biology, we engineered a modi®ed adenovirus to carry the HIV-1 vpr gene product in order to facilitate delivery of Vpr into dierent human tumor cell lines and study its biology.
Adenovirus is a medium-sized, icosahedral virus that contains a double-stranded linear DNA genome. Adenovirus replication occurs in the nucleus of infected cells and the viral DNA does not integrate into the host genome. Replication-defective (E1A and E1B deletion) adenoviral vectors can accommodate up to 7.5 kb of foreign genes and can be ampli®ed to high titers in 293 cells (Davis et al., 1998) .
The advantages of utilizing an adenovirus delivery system to study Vpr biology include:
(a) Broad tissue tropism. Adenoviruses can infect a broad range of tissues in humans without being complemented in-trans with additional viral proteins; (b) Stability. Viral stocks can be mass-produced and tittered, then stored for years without apparent decrease in infectivity; (c) Well established production techniques. Adenovirus has become a vector of importance for human therapeutic gene delivery; as a result, systems for production, titration and storage have been optimized; (d) Ready availability of replication-defective strains.
The currently used adenoviral vectors have deletions in E1A and E1B and are replication-defec-tive in vivo thus minimizing unnecessary viral spread; (e) No evidence of integration. The adenovirus genome remains episomal, minimizing the chance of integration-related activation of proto-oncogenes or inactivation of tumor-suppressor genes; and (f) High level expression. The delivery of genes by adenovirus results in high levels of protein production, which may overcome host resistance Ketner, 1989, 1990; Perkus et al., 1995; Fisher et al., 1996; Jolly, 1994; Qazilbash et al., 1997; Davis et al., 1998) . Additionally and importantly, this system allows examination of a lentiviral gene and its product in the absence of other lentiviral gene products.
We demonstrate here that adCMV-vpr delivers high levels of the vpr gene into cells resulting in signi®cant Vpr expression. The adCMV-vpr inhibits proliferation of a wide variety of tumor cells and blocks cell cycle progression at the G 2 /M phase. Cell cycle arrest induced by adCMV-vpr is highly correlated with tumor cell apoptosis via the mitochondria dependent caspase 9 pathway. The adCMV-vpr inhibits tumor cell proliferation and induces apoptosis irrespective of p53 status. Furthermore, Bcl-2 overexpression in tumor cell lines does not inhibit apoptosis by this vector-gene combination. adCMV-vpr appears a useful reagent for the study of the eects of Vpr on tumor cell lines and may be useful for understanding mechanisms of inhibiting abnormal cell growth.
Results

Construction and generation of recombinant adCMV-vpr
The structure of the plasmids used to produce adCMVvpr and adCMV-lacZ are depicted in Figure 1 . The DNA fragment containing the HIV-1 strain 89.6 was used as a template for construction of the pAdCMV-vpr. The plasmid containing a b-galactosidase gene was used to construct pAdCMV-lacZ, the negative control. Brie¯y, after PCR ampli®cation the product was puri®ed and the pAdCMV-Link1 vector was digested with HindIII and XbaI restriction enzymes and the fragments were ligated at 1 : 1 molar ratio. Positive clones were identi®ed by restriction digestion and the correct clones were con®rmed by DNA sequencing. Figure 2a shows well-de®ned bands around 300 bp in the pAdCMV-vpr lane. A vpr plasmid (pcDNA-vpr) was used as a positive control (Figure 2a ). The pAdCMV-vpr plasmid and the adenoviral vector construct sub 360 were both linearized and co-transfected into 293 cells. Following viral culture a large quantity of Vpr adenovirus was puri®ed by centrifugation. Titers of the viral stocks were determined by plaque formation on 293 cells.
Expression of the Vpr transgenes in infected cells
Western blotting was performed to examine the expression of adCMV-vpr. HeLa cells were infected with 5610 6 adCMV-vpr or adCMV-lacZ and the expression of Vpr protein in the infected cells was examined 48 h post infection. The cells infected with adCMV-vpr generated a 14 kDa protein band (lane B) which matches the size of baculo-virus puri®ed HIV-1 Vpr protein (lane A), detected with the anti-Vpr polyclonal antibody (Muthumani et al., 2000b) . There was no Vpr protein expression observed in adCMVlacZ infected cells (lane C) (Figure 2b ).
Transduction rate of adCMV-lacZ in different cell lines and in vivo expression of adCMV-vpr
The number of cells exhibiting lacZ expression increased in proportion to the MOI of all ®ve-tumor cell lines tested (Figure 2c ). The lacZ gene was expressed in at least 20% of target cells in each cell line at an MOI of 1 and was expressed in 85 ± 90% of Figure 1 Schematic outline of the recombinant adenovirus production target cells at MOI of 100. These results con®rm that these human cell lines are all susceptible to adenovirus infection. The transduction eciencies (per cent) of this adenovirus vector system ranged from 38.0+3 and 82.0+4.3 in HeLa, to 22.0+2.5 and 55+3.0 in SK-N-AS at an MOI of 1 and 10 respectively (Figure 2c ).
Cell death induced by adCMV-vpr in cancer cells: effect on morphology and viability
We investigated the eects of adCMV-vpr infection on cell morphology in the oncogenic cell lines. HeLa, TE671; ZR-75-1 and SK-N-AS. Cell morphology was examined by bright-®eld microscopy 96 h post infection (Figure 3 ). Cells infected with adCMV-vpr became retracted and rounded. We observed a reduction in the overall number of cells per ®eld due to cell detachment from the tissue plates, indicating abnormal physiological condition and subsequent cell death during the period of infection. In contrast, adCMV-lacZ infection appeared to have little eect on cell viability. Figure 4 shows a typical trypan blue exclusion assay 96 h post infection. Viability of HeLa, TE-671, LnCap, SK-N-AS, ZR75-1 and Jurkat cell lines was studied at dierent time points. Analysis of adCMV-vpr induced cell death in target cells revealed an increase in cell death over time. 28+8.0% of HeLa cells infected with adCMV-vpr were dead 24 h post infection increasing to 71.6+8.0% by 96 h post infection. Similar results were observed for TE671, LnCap, SK-N-AS, ZR75-1 and Jurkat, as 65.3+8.1%; 67+8.0%; 56.6+5.5%; 72.3+6.1% and 76.6+6.8% respectively were dead at 96 h. In contrast, the adCMV-lacZ infected group remained mostly viable throughout each experiment (P50.001).
Effect of adCMV-vpr on cell cycle arrest
The ability of adCMV-vpr to arrest the cell cycle at G 2 / M phase was examined by infecting and later staining harvested tumor cells for DNA content with propidium iodide as previously described (Muthumani et al., 2000b) . DNA content was determined by¯ow cytometry. Characterization at dierent intervals post infection provided a more complete picture of the life cycle kinetics of the infected cell lines. Figure 5 shows the proportion of cell cycle arrest in mock, adCMV-lacZ, and adCMV-vpr infected cells in G 2 phase at various time points post infection. adCMV-vpr infected cells were much more likely to be in G 2 /M phase at 144 h post infection, HeLa (59.0+5%); LnCap (63.3+5%); TE671 (64.2+10%); ZR-75-1 (62.1+5%); SK-N-AS (43.0+4%) and Jurkat (59.2+9%). G 2 /M arrest was observed much less frequently in the adCMV-lacZ infected cells and not at all in the control cells suggesting a small but real dierence between adCMV-lacZ and no infection. Taken together one can see that adCMV-vpr infection leads to cell cycle arrest at the G 2 /M phase in diverse tumor lines.
adCMV-vpr induced apoptosis
Flow cytometry analysis was used to measure Annexin V binding as an apoptosis-speci®c signal to further delineate the mechanism of adCMV-vpr induced tumor 
adCMV-vpr activates the apoptosis pathway by activating mitochondrial caspase 9
To investigate the mechanism by which adCMV-vpr induced apoptosis in tumor cell lines, we examined cytochrome c release and the eects of caspase activation. During the process of apoptosis induction through the mitochondrial pathway, cytochrome c is released from the mitochondria, activating Apaf-1, which leads to caspase 9 activation, which then activates caspase 3 and the downstream components of the mitochondrial apoptotic pathway (Li et al., 1997) . Cytosolic fractions were prepared from infected tumor cell lines 48 h post infection to investigate whether cytochrome c release is induced by adCMVvpr infection. Tumor cells were infected with either adCMV-vpr or the adCMV-lacZ control vector. Cytochrome c levels were increased in the cytosol at 48 h post infection in all adCMV-vpr cell lines tested but not in the adCMV-lacZ infected cells or mock infected cells (Figure 7a ).
We next examined the eects of adCMV-vpr on the activation of after relevant caspase pathways. Tumor cells infected with adCMV-lacZ or adCMV-vpr or mock-infected cells were lysed and protein concentration was determined. Lysates containing 100 mg of total protein were analysed for each experimental group. Caspase-speci®c chromagenic substrates were mixed with cell lysate, and the amount of substrate released was determined. Importantly, we observed that there was no activation of the caspase 8 pathway by adCMVvpr. All infected tumor cells exhibited the same background level of caspase 8 activity as mock infected cells (data not shown). This result supports that activation was occurring through the caspase 9 pathway.
Signi®cantly, more caspase 9 activity was seen in adCMV-vpr infected tumor cells when compared to adCMV-lacZ or mock-infected cells. The pattern of caspase 9 activation by adCMV-vpr was highly reproducible. These results are consistent with the hypothesis that adCMV-vpr leads to apoptosis of (Figure 7b ). The measurement of caspase 9 activity should be very useful in characterizing Vpr induced apoptosis activity in screening assays. The positive controls for this assay were 5U of the recombinant human caspase 9. One unit of the recombinant caspase 9 contains enzymatic activity that cleaves 1 nmol of caspase substrate LEHD-pNA per hour at 378C at the saturated substrate concentration. Negative controls included reactions performed in the presence of competitive inhibitors (LEAD-FMK for caspase 9) that carry cleavage sites for the caspase. Caspase ELISA then quanti®ed the amount of monoand oligonucleosomes generated from each sample and these results con®rmed that caspase 9 plays a major role in Vpr induced apoptosis in adCMV-vpr infected cells.
Analysis of Bcl-2 proteins in adCMV-vpr expressing cells
We then set out to determine if Vpr induced apoptosis is prevented by genes known to be involved in the regulation of apoptosis. Jacotot et al. (2001) , studying isolated mitochondria and synthetic Vpr protein, recently reported that Vpr interacts with the adenine nucleotide translocator (ANT) at the mitochondrial inner membrane and concluded that both Vpr and Bcl-2 modulate mitochondrial membrane permeabilization through a direct interaction with ANT. Using isolated mitochondria they reported inhibitory eects on Vpr induced apoptosis by Bcl-2. The inhibitory eect is mediated, they speculate, through a direct interaction of Bcl-2, ANT and Vpr. However, their study did not examine Vpr biology in living cells. Accordingly, we screened for Bcl-2 overexpressing cells and examined their susceptibility to Vpr induced apoptosis using the Figure 8 , illustrating high Bcl-2 expression in some cells. We compared the Bcl-2 levels in the dierent cell lines with the apoptosis induced by adCMV-vpr. In HeLa, ZR75-1 and Jurkat cells, we detected a high level of Bcl-2 by Western blot, whereas no detectable level of Bcl-2 expression was observed in TE671 and SK-N-AS. In all cells, however, adCMV-vpr infection induced high levels of apoptosis illustrating the inability of Bcl-2 expression to protect these tumors from adCMV-vpr driven apoptosis.
p53 independent apoptosis by adCMV-vpr
In order to further con®rm that Vpr induces apoptosis, which is independent from p53 status, we next tested the Saos2 cell (osteosarcoma) line for adCMV-vpr induced apoptosis. This cell line is a gene deleted p53 null line which can not appears p53. Cells were infected with adCMV-vpr or adCMV-lacZ 48 or 96 h post infection by gating on the propidium iodide (PI)-negative (non-necrotic) population. Annexin-V analysis 48 h post infection revealed a greater level of apoptosis in the adCMV-vpr infected cells (19.2%) compared with adCMV-lacZ infected (4.25%). This induction of apoptosis was apparent when the cells were infected for 48 h (Figure 9a ,b). We observed a dramatic level of cell death (60%) induced by adCMV-vpr in this cell line, which clearly showed that p53 status is not a prerequisite for adCMV-vpr induced apoptosis. adCMV-vpr infection/administration can induce apoptosis in cancer cells independent from p53 status ( Figure 10 ).
Discussion
Neoplastic growth develops when initial mutations alter control of the cell cycle resulting in a loss of cellular response to apoptosis. Cancer cells exhibit loss of dierentiation markers, a lack of contact inhibition, and develop the ability to undergo metastasis. Many of the mutations that contribute to the development of cancer have been found to either activate protooncogenes or inactivate tumor suppressor genes (Hanaham and Weinberg, 2000; Rountree et al., 2001; Stirewalt and Radich, 2000) . damage before replicating their DNA and passing these mutations to daughter cells. Increased p53 activity can also lead to apoptosis through the up regulation of pro-apoptotic genes in cells that fail to repair their DNA and try to breach the cell cycle. In cells with p53 inactivating mutations, cell division will continue regardless of DNA damage, accumulating more mutations and ultimately resulting in malignant cell growth. Certain viral infections contribute to oncogenesis by activating proto-oncogenes or inactivating tumor suppressor genes (Wyllie, 1997; Rozenszajn et al., 2000; Stirewalt and Radich, 2000) . For example, Human Papilloma Virus induces cervical carcinomas, when the E6 viral protein binds to p53, causing inactivation and ultimate degradation of p53. Some viruses also carry oncogenes within their viral genomes. These virally derived oncogenes also aect cell cycle regulation. For example, the Harvey sarcoma virus carries the ras oncogene, which is an important factor in signal transduction and cell cycle progression (Sefton et al., 1982; Newbold, 1984; Wigler, 1990) . The restoration of normal tumor suppressor protein (p53) function may provide a useful mechanism to augment conventional modalities such as chemotherapy, radiotherapy, immunotherapy as well as surgery and is currently being tested clinically. Recombinant adenovirus has been studied as a vector to deliver the wild type p53 gene to inhibit tumor cell growth (Komata et al., 2000; Qi et al., 2001) . HIV-1 Vpr has been shown to aect tumor cells in ways similar to that of p53 and other tumor suppressor genes. Several laboratories, including our own have previously reported that HIV-1 Vpr induces apoptosis following induction of G 2 /M cell cycle arrest (He et al., 1995; Ayyavoo et al., 1997; Goh et al., 1998; Boon et al., 1998; Stewart et al., 1999) in some tumor lines (Sawaya et al., 1998; Shostak et al., 1999) . However, the mechanism of Vpr induced tumor cell apoptosis is not understood.
Vpr expression is currently accomplished via plasmid transfection in established cell lines or by retroviral infection. Plasmid transfection is very inecient in primary cells, including human T-cells and monocyte cell lines and similarly retroviruses have limited tropism and lower level of gene delivery than adenovirus. We decided to focus on the development of an Adenoviral delivery system. Adenovirus has been well characterized as a viral delivery system in both experimental and clinical applications. Several features make it an important research tool including its broad tropism, enabling it to deliver genes to a variety of human cells in vitro (Lynch et al., 1997; Athanasopoulos et al., 2000). Extensive research has produced adenovirus with early gene deletions creating a virus that only replicates in packaging cell lines making it safer to manipulate (Vincent et al., 1997; Kunke et al., 2000) . Additionally, adenovirus is stable at room temperature and is easy to manufacture. Recombinant adenovirus carrying the HIV-1 vpr gene is suitable for the study of the long-term eects of Vpr in vivo, since cells will continuously synthesize Vpr until the delivered viral DNA becomes degraded.
We next used this novel tool to address issues important to Vpr biology. In this regard recent work has suggested that the mitochondria play a central role in the generation of apoptosis by releasing cytochrome c, which activates the caspase apoptotic cascade (Finkel, 2001 ). Currently there is little understanding of the mitochondrial or post mitochondrial events induced by viral borne delivery of Vpr. Only the eects ) were infected with adCMV-vpr or adCMV-lacZ. 96 h post infection the cytosolic fraction was extracted and was used to analyse cytochrome c release. Lysates containing cytochrome c were adsorbed onto the plastic surface of 96-well plates as described in Materials and methods. (b) For caspase 9 analysis, 100 mg of protein from each cell lysate were used in the assay as described in Materials and methods. Each column and error bar represents the mean standard deviation of results from three dierent experimental samples; each experiment was performed three independent times. The positive controls for this assay were 5 U of the recombinant human caspase 9 Figure 8 Bcl-2 analysis. Eect of adCMV-vpr on cells expressing Bcl-2. The intracellular expression of Bcl-2 was analysed in dierent tumor lines as described in Materials and methods. Infected cells (HeLa, ZR-75-1 and Jurkat) express high levels of Bcl-2. The arrow indicates the 26 kDa protein band of Bcl-2. MCF7 cells were used as a positive control of Vpr protein in isolated mitochondria has been examined (Jacotot et al., 2001) and no downstream events have been studied. We tested the eects of adCMV-vpr infection on cytochrome c and speci®c downstream caspase activity. Cell lines infected with adCMV-vpr, released a signi®cant amount of cytochrome c and this was coupled with subsequent increases in caspase 9 activity. Alternatively, infection with adCMV-vpr had little eect on caspase 8 activity. This ®nding supports the assertion that Vpr does not act through the Fas FADD pathway that results in caspase 8 activation (Patel et al., 2000) . On the contrary, adCMV-vpr infection leads to apoptosis via cytochrome c release from mitochondria followed by caspase 9 activation, which activates caspase 3.
We examined the eect of adCMV-vpr in several dierent cell lines, including HeLa (cervical carcinoma; p53 null (May et al., 1991) ), TE671 (medulloblastoma; p53 mt) (Valenzuela et al., 2000) , ZR-75-1 (breast cancer; p53 wt) (Toma et al., 1998) , Jurkat (leukemia; p53 wt) (Rozenszajn et al., 2000) , LnCap (prostate; p53 wt) (Planchon et al., 1995) and SK-N-AS (neuroblastoma; p53 wt) (Brooks et al., 2000) . adCMV-vpr induced dramatic apoptosis in as little as 12 h in each cell line tested. We speculated that the eciency of delivery of the adCMV-vpr could overcome limitations of the p53 pathway. We observed that HIV-1 Vpr induces apoptosis when delivered via adenovirus in cells with p53 activity ranging from normal activity to no p53 activity. For example, LnCap has normal wild type p53 activity, and adCMV-vpr infection of this cell line induced apoptosis in 80% of cells within 2 days of infection. Similarly, adCMV-vpr infection induced apoptosis in 70% of HeLa cells, which lack p53 expression but has the p53 alleles, in the same period. adCMV-vpr induced a similar level of cell death in the TE671 cell line, which contains a p53 mutation. In order to further con®rm that Vpr induces apoptosis, which is independent from p53 status, we next tested the Saos2 cell (osteosarcoma) line for adCMV-vpr induced apoptosis. In this cell both p53 alleles are deleted by recombination and therefore this line is a true p53 null line. We observed a dramatic level of cell death (60%) induced by adCMV-vpr in this cell line (Figure 9 ), which clearly illustrates that p53 status is not a prerequisite for adCMV-vpr induced apoptosis.
We also found that adCMV-vpr induces apoptosis in cells irrespective of their Bcl-2 expression levels. The eect of Vpr on apoptosis was speculated to be competed by Bcl-2 (Jacotot et al., 2001) . However, we did not observe this eect (Figure 8 ). As HeLa, Jurkat, and the adenocarcinoma cell line ZR75-1 all express high levels of Bcl-2 yet are all susceptible to adCMV-vpr driven apoptosis. It would appear that Vpr delivered by adenoviral infection is expressed at high enough levels to interact with its mitochondrial target and induce the mitochondria dependent apoptosis pathway even in the presence of Bcl-2.
Cancer is often caused by the dysregulation of the cell cycle and a lack of speci®c apoptosis. Understanding the mechanisms of reversion of cancer cells to these normal regulated pathways provides a potentially important approach to developing treatments for neoplasia. A major function of tumor suppressor proteins appears to be the controlled induction of cell-cycle arrest or apoptosis (Figure 10 ). The delivery of tumor suppressor genes or proteins represents a straightforward strategy for developing approaches to cancer therapy. For example, delivery of the p53 gene into cancer cells by recombinant adenovirus inhibits the growth of some cancer cells (Perkus et al., 1995; Qazilbash et al., 1997) . However, this strategy only functions in cancer cells without wild type p53 activity.
In certain cancer cells, wild type p53 is still present, but other factors inactivate p53. For example, HeLa cells express wild type p53, but the Human Papilloma Virus E6 protein suppresses its activity. It is also possible that wild type p53 fails to send an apoptotic signal to downstream important factors, such as Bax. For cancer cells with wild type p53, delivering additional p53 only increases the quantity of tumor suppressor protein but does not result in cell cycle arrest or apoptosis. For example, it has been reported that delivery of p53 into p53 wt cancer cells fails to suppress cell proliferation (Gilboa, 1999; Bonnet et al., 2000) . Clearly genes that complement this activity are important to study.
The adCMV-vpr activity appears independent of p53 status as it activates the caspase 9 dependent mitochondrial apoptosis pathway, which is downstream of p53 activity (Figure 10) . Therefore, adCMV-vpr can induce apoptosis in cancer cells independent from p53 status. Accordingly, the adCMV-vpr developed here is an important tool for understanding the biology of tumor cell escape. It is interesting to speculate that many tumorigenic viruses have acquired mechanisms to inhibit host tumor suppressor genes or proteins. However, it is unlikely that tumorigenic viruses will have developed a mechanism to inhibit Vpr function since it is not a host protein and it is thought to have only infected humans within the last century. In this regard, the adCMV-vpr may be an important tool for dissection of tumor cell regulation and suggests that further investigation of such vectors is warranted.
Materials and methods
Cell culture
The HeLa, TE671, ZR75-1, SK-N-AS, Jurkat, LnCap and embryonal kidney cell line (293) were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). HeLa, TE671, 293 and SK-N-AS were grown in a Dulbecco's Modi®ed Eagle's medium; Jurkat and LnCap were grown in RPMI1640 medium containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin G, and 100 mg/ml streptomycin. ZR75-1 cells were grown in RPMI1640 medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/l sodium bicarbonate and 10% FBS. The cells were grown at 378C in a humidi®ed atmosphere of 5% CO 2 and 95% air.
The construction of pAdCMV-vpr
The provirus construct of HIV-1 strain 89.6 was used as a template for vpr, and the primers used were: 5'-AAAAGCTT-GATGGAACAAGCCCCAGAAGACC-3' and 5'-AATCTA-GACTAGGATTTACTGG CTCCATTT-3' with the restriction sites underlined. The PCR cycling conditions were: 948C for 4 min, 948C for 1 min ? 548C for 45 s ? 728C for 30 s for 30 cycles, and extensions 728C for 9 min in a Stratagene-Robocycler Gradient-40 cycler using Taq DNA Polymerase (Boehringer Mannheim, IN, USA). After PCR, the product was puri®ed using a PCR puri®cation kit (Qiagen, CA, USA) according to the manufacturer's protocol. Puri®ed PCR product as well as pAd.CMV-Link1 vector were digested with restriction enzymes HindIII and XbaI (New England Biolabs, MA, USA) and the 300 bp and 6.7 kb fragments were cut from an agarose gel and puri®ed using a gel puri®cation kit (Qiagen, CA, USA) according to the manufacturer's protocol. Ligation of the two fragments was performed at a 1 : 1 molar ratio using T4 ligase (NEB, MA, USA), followed by transformation into competent bacterium Stbl2 (GIBCO BRL, CA, USA). Positive clones were selected after restriction with HindIII and XbaI, and the identi®ed clones were con®rmed by DNA sequencing.
The generation of adCMV-vpr
The pAdCMV-vpr plasmid was linearized with NheI (New England Biolabs, MA, USA), and puri®ed from low-melting agarose gel. Adenoviral construct sub 360 was linearized with ClaI (NEB, MA, USA). The linearized pAdCMV-vpr and sub 360 were co-transfected into 293 cells using DOTAP transfection agent (Boehringer Mannheim, MN, USA). Twenty hours after transfection, the cell cultures were overlaid with agar. After 5 days, the cultures were monitored for plaque formation. Plaques were propagated in 293 cells, tested for vpr insertion into the viral genome by PCR, and subsequently analysed by Southern blot. Batch quantities of Vpr adenovirus were puri®ed by culture centrifugation in a CsCl 2 density gradient. Similarly, co-transfection of 293 cells with pAdCMV-lacZ (containing the E.coli b-galactosidase gene) and the sub 360 adenoviral constructs generated the control adenovirus adCMV-lacZ. Titers of all stocks were determined by plaque formation in 293 cells with agar overlay. The adenovirus vector concentration was determined by measuring the optical density at 260 nm and was expressed as optical particle units (OPU) as described by Mittereder et al. (1996) .
In vitro adenoviral-mediated lacZ expression
HeLa, TE-671, ZR75-1, LnCap and SK-N-AS cells were plated in 6-well culture plates during the exponential growth phase at a density of 5610 5 cells per well 24 h before adCMV-lacZ infection. The culture medium was aspirated immediately before infection, and an adenovirus suspension was distributed over the monolayers at various (0 ± 100) multiplicities of infection (MOI). After 24 h incubation at 378C in the presence of 5% CO 2 , b-D-galactosidase expression was evaluated using X-gal as the substrate as previously described (Miyake et al., 1996) . Blue precipitate that appeared in the cell indicated b-D-galactosidase expression. In vitro studies of each adenovirus in dierent cell lines was shown to give satisfactory gene transfer without signi®cant cytotoxicity at MOI of 10, as revealed by the adCMV-lacZ control assay (Sawada et al., 1996) (data not shown).
Western blot analysis
HeLa cells (5610 6 ) were infected with adCMV-vpr and adCMV-lacZ. The infected cells were collected 48 h later, washed twice in ice-cold PBS, and solubilized in 500 ml of cell lysis buer containing 50 mM HEPES (pH 7.0), 150 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40, 0.2 mM Pefabloc, 100 mM Na 3 VO 4 , 10 mM b-glycerophasphate, 1 mM NaF, and 10 mg (each) of aprotinin, pepstatin, and leupeptin per ml for 30 min at 08C after sonication. In addition, all adCMV-vpr infected or mock cell proteins were extracted using the same buer for Bcl-2 analysis. Cell lysates were centrifuged for 10 min at 08C and the cell extracts were dialyzed against 20 mM Tris (pH 7.5), 5 mM NaCl, 10% glycerol, 0.1 mM EDTA, 1 mM DTT. The ®nal protein concentrations of the extracts were measured with the Bradford reagent (Bio-Rad, CA, USA), using pooled bovine gamma globulin as a standard. Immunoblotting was performed, following denaturing of samples and gel separation by SDS ± PAGE using the enhanced-chemiluminescence detection system. Brie¯y, 50 mg of adCMV-vpr, and adCMV-lacZ and 10 mg of baculopuri®ed Vpr protein (Muthumani et al., 2000a) were loaded on 12% SDS-polyacrylamide gels and electroblotted to PVDF-membranes (Immobilion P; Millipore, CA, USA). 100 mg of adCMV-vpr infected cell protein were used for Bcl-2 expression analysis. Filters were blocked in blocking buer containing 3% non-fat dry milk and 0.02% Tween 20. After washing, the ®lter was incubated with anti-Vpr antibodies raised in rabbits (1 : 500) (Muthumani et al., 2000a) and antiBcl-2 antibodies (Oncogene Research Products, MA, USA) in blocking solution overnight at 48C. After being washed twice, the ®lter was incubated with 1 : 1000 horseradish peroxidaseconjugated secondary antibody (Boehringer Mannheim, MN, USA). After the ®nal washing, immunoreactivity was visualized using the ECL system (Amersham Pharmacia Biotech Ltd.).
Cell cycle analysis
The tumor cell lines (1610 6 ) were grown in 35 mm-diameter dishes and then infected with adCMV-vpr or adCMV-lacZ. Cells were harvested 1, 2, 4 or 6 days post infection, washed with PBS twice, trypsinized, and then incubated with 1 mg/ml RNaseA and 10 mg/ml propidium iodide in PBS for 30 min on ice using a Cycle Test kit (Becton Dickinson, CA, USA). Cellular DNA content in the ®xed cells was then assessed with a FACScan¯ow cytometer and analysed with the ModFit LT program (Becton Dickinson, CA, USA). The percentage of cells in G 2 /M was compared to that of mock infected and adCMV-lacZ infected cells. The cell cycle phase distribution was quanti®ed and presented with standard deviation from at least three independent sets of measurements for statistical signi®cance.
Apoptosis analysis by flow cytometry
FACS analysis was performed to quantify apoptosis in target cells. Following infection, Annexin-V staining was performed as recommended by the manufacturer (PharMingen, CA, USA). In brief, the infected cells (1610 6 ) were harvested and washed twice with PBS (pH 7.2). Cells were resuspended in binding buer (0.1 M HEPES (pH 7.4); 1.4 M NaCl; 25 mM CaCl 2 ), stained with Annexin V and vital dye (PI) and incubated for 30 min at room temperature in the dark. Cells were washed once with binding buer, and resuspended in 400 ml of binding buer and subsequently analysed by FACS (Becton Dickinson, CA, USA) analysis. Data was analysed by the CELL-Quest program (Becton Dickinson, CA, USA).
Trypan blue exclusion assay for cell viability
Cells were plated at 1610 5 cells/ml onto 6-well plates and allowed to adhere overnight. The following day, cells were infected with 10 PFU/cell of adCMV-lacZ or adCMV-vpr particles in 1 ml serum-free medium. Two hours post infection, serum medium was added to each dish at a ®nal serum concentration of 5%. Supernatants were removed, cells were trypsinized and the supernatants and cells were combined at the indicated times. Trypan blue (GibcoBRL, MD, USA) was added to a ®nal concentration of 0.02% to determine viability. Cells were counted on a hemacytometer (a total of 600 to 1000 cells per time point).
Caspase analysis
Caspase 9 (Mch6, ICE-LAP6) activity was determined according to the manufacturer's instructions (MBL, Nagoya, Japan). Cells were lysed in cell lysis buer (10 mM Tris-HCl; 10 mM NaHPO 4 (pH 7.5); 130 mM NaCl; 1% Triton X-100; 10 mM sodium pyrophosphate) 96 h after infection. The cell lysate (100 mg/100 ml protein) was incubated with the LEHDpNA (caspase 9) substrates for 1 ± 2 h at 378C. The release of pNA was determined using a microplate reader reading at 405 nm (MBL, Nagoya, Japan). Five U of each recombinant human caspase 9 were used as positive controls for this assay. One unit of recombinant caspase 9 contains enzymatic activity that cleaves 1 nmol of caspase substrate LEHDpNA per hour at 378C at the saturated substrate concentration. Negative controls included reactions performed in the presence of competitive inhibitors (LEAD-FMK for caspase 9) that carry the cleavage sites for the caspase (MBL, Nagoya, Japan).
Quantification of cytochrome c by immunoassay
Cytochrome c distribution in apoptotic cells was determined by subcellular fractionation, extraction and solubilization described previously with minor modi®cation (Kharbanda et al., 1997) . Brie¯y, 5610 6 cells were harvested 96 h post infection and washed with PBS. The cells were suspended in Buer A (20 mM HEPES-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 250 mM sucrose, 16 protease inhibitor cocktail) and homogenized by a Dounce homogenizer. Unbroken cells and nuclei were pelleted at 10 000 g for 10 min at 48C, and then removed. The supernatant was further centrifuged at 10 000 g for 20 min. The supernatant was saved as a cytosolic fraction while the precipitate was dissolved in buer containing 0.5% (v/v) NP40 and saved as the mitochondrial fraction. The cytosolic fraction was used to analyse cytochrome c release. Cytochrome c was adsorbed onto the plastic surface of 96-well plates and quanti®ed as per the cytochrome c ELISA kit instructions (Oncogene Research products, Cambridge, MA, USA).
Statistical methodology
The Student's t-test was used to determine the statistical signi®cance of dierences between experimental groups, when indicated.
